ABL1 is altered in 0.9% of pancreatic carcinoma patients [2].

ABL1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ABL2 is altered in 0.37% of pancreatic carcinoma patients [2].

ABL2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ABL2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ACVR1B is altered in 3.43% of pancreatic carcinoma patients [2].

ACVR1B is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ACVR1B status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

AKT1 is altered in 0.59% of pancreatic carcinoma patients [2].

AKT1 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

AKT2 is altered in 2.75% of pancreatic carcinoma patients [2].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT3 is altered in 0.9% of pancreatic carcinoma patients [2].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ALK is altered in 1.92% of pancreatic carcinoma patients [2].

ALK is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ALK status and pancreatic carcinoma as inclusion criteria, 3 are phase 2 (2 open) [3].

APC is altered in 2.59% of pancreatic carcinoma patients [2].

APC is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ARAF is altered in 0.4% of pancreatic carcinoma patients [2].

ARAF is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ARID1A is altered in 8.82% of pancreatic carcinoma patients [2].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ASXL1 is altered in 1.08% of pancreatic carcinoma patients [2].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ASXL1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ATM is altered in 4.18% of pancreatic carcinoma patients [2].

ATM is an inclusion eligibility criterion in 6 clinical trials for pancreatic carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ATM status and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (4 open) [3].

ATR is altered in 1.38% of pancreatic carcinoma patients [2].

ATR is an inclusion eligibility criterion in 4 clinical trials for pancreatic carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATR status and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [3].

ATRX is altered in 1.19% of pancreatic carcinoma patients [2].

ATRX is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATRX status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BACH1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BACH1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BARD1 is altered in 1.16% of pancreatic carcinoma patients [2].

BARD1 is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain BARD1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

BCL2 is altered in 0.49% of pancreatic carcinoma patients [2].

BCL2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BCL6 is altered in 0.8% of pancreatic carcinoma patients [2].

BCL6 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BLM is altered in 1.11% of pancreatic carcinoma patients [2].

BLM is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BRAF is altered in 2.49% of pancreatic carcinoma patients [2].

BRAF is an inclusion eligibility criterion in 7 clinical trials for pancreatic carcinoma, of which 7 are open and 0 are closed. Of the trials that contain BRAF status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [3].

BRCA1 is altered in 2.0% of pancreatic carcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 10 clinical trials for pancreatic carcinoma, of which 9 are open and 1 is closed. Of the trials that contain BRCA1 status and pancreatic carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [3].

BRCA2 is altered in 5.08% of pancreatic carcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 10 clinical trials for pancreatic carcinoma, of which 9 are open and 1 is closed. Of the trials that contain BRCA2 status and pancreatic carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [3].

BRIP1 is altered in 1.28% of pancreatic carcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain BRIP1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

BTRC is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BTRC status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

C11orf30 is altered in 0.2% of pancreatic carcinoma patients [2].

C11orf30 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains C11orf30 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CCND1 is altered in 0.96% of pancreatic carcinoma patients [2].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12 is altered in 1.52% of pancreatic carcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 5 clinical trials for pancreatic carcinoma, of which 4 are open and 1 is closed. Of the trials that contain CDK12 status and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 2 (3 open) [3].

CDK4 is altered in 0.86% of pancreatic carcinoma patients [2].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK6 is altered in 1.34% of pancreatic carcinoma patients [2].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN1A is altered in 0.27% of pancreatic carcinoma patients [2].

CDKN1A is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CDKN1B is altered in 0.61% of pancreatic carcinoma patients [2].

CDKN1B is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CDKN2A is altered in 30.7% of pancreatic carcinoma patients [2].

CDKN2A is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

CHD4 is altered in 1.27% of pancreatic carcinoma patients [2].

CHD4 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CHD4 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CHEK1 is altered in 0.51% of pancreatic carcinoma patients [2].

CHEK1 is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain CHEK1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

CHEK2 is altered in 0.8% of pancreatic carcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 4 clinical trials for pancreatic carcinoma, of which 4 are open and 0 are closed. Of the trials that contain CHEK2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

CRKL is altered in 0.36% of pancreatic carcinoma patients [2].

CRKL is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CSF1R is altered in 0.92% of pancreatic carcinoma patients [2].

CSF1R is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CYLD is altered in 0.77% of pancreatic carcinoma patients [2].

CYLD is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CYLD status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

DDR2 is altered in 0.82% of pancreatic carcinoma patients [2].

DDR2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

DICER1 is altered in 1.15% of pancreatic carcinoma patients [2].

DICER1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DICER1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

DNMT3A is altered in 1.15% of pancreatic carcinoma patients [2].

DNMT3A is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

DVL1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DVL1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

EGFR is altered in 1.0% of pancreatic carcinoma patients [2].

EGFR is an inclusion eligibility criterion in 4 clinical trials for pancreatic carcinoma, of which 4 are open and 0 are closed. Of the trials that contain EGFR status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

EPCAM is altered in 0.26% of pancreatic carcinoma patients [2].

EPCAM is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EPHA2 is altered in 0.17% of pancreatic carcinoma patients [2].

EPHA2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is altered in 2.14% of pancreatic carcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 7 clinical trials for pancreatic carcinoma, of which 6 are open and 1 is closed. Of the trials that contain ERBB2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 5 are phase 2 (5 open) [3].

ERBB3 is altered in 1.76% of pancreatic carcinoma patients [2].

ERBB3 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

ERBB4 is altered in 1.76% of pancreatic carcinoma patients [2].

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC2 is altered in 1.54% of pancreatic carcinoma patients [2].

ERCC2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC3 is altered in 0.41% of pancreatic carcinoma patients [2].

ERCC3 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC4 is altered in 0.7% of pancreatic carcinoma patients [2].

ERCC4 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC4 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC5 is altered in 0.95% of pancreatic carcinoma patients [2].

ERCC5 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC5 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC6 is altered in 0.5% of pancreatic carcinoma patients [2].

ERCC6 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC6 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

EXO1 is altered in 0.26% of pancreatic carcinoma patients [2].

EXO1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EZH2 is altered in 0.48% of pancreatic carcinoma patients [2].

EZH2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FANCA is altered in 1.73% of pancreatic carcinoma patients [2].

FANCA is an inclusion eligibility criterion in 5 clinical trials for pancreatic carcinoma, of which 5 are open and 0 are closed. Of the trials that contain FANCA status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

FANCB is altered in 0.28% of pancreatic carcinoma patients [2].

FANCB is an inclusion eligibility criterion in 4 clinical trials for pancreatic carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCB status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

FANCC is altered in 0.47% of pancreatic carcinoma patients [2].

FANCC is an inclusion eligibility criterion in 4 clinical trials for pancreatic carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCC status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

FANCD2 is altered in 11.5% of pancreatic carcinoma patients [2].

FANCD2 is an inclusion eligibility criterion in 4 clinical trials for pancreatic carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCD2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

FANCE is altered in 0.73% of pancreatic carcinoma patients [2].

FANCE is an inclusion eligibility criterion in 4 clinical trials for pancreatic carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCE status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

FANCF is altered in 0.42% of pancreatic carcinoma patients [2].

FANCF is an inclusion eligibility criterion in 4 clinical trials for pancreatic carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCF status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

FANCG is altered in 1.64% of pancreatic carcinoma patients [2].

FANCG is an inclusion eligibility criterion in 4 clinical trials for pancreatic carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCG status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

FANCI is altered in 1.69% of pancreatic carcinoma patients [2].

FANCI is an inclusion eligibility criterion in 4 clinical trials for pancreatic carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCI status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

FANCL is altered in 0.87% of pancreatic carcinoma patients [2].

FANCL is an inclusion eligibility criterion in 4 clinical trials for pancreatic carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCL status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

FANCM is altered in 2.56% of pancreatic carcinoma patients [2].

FANCM is an inclusion eligibility criterion in 4 clinical trials for pancreatic carcinoma, of which 4 are open and 0 are closed. Of the trials that contain FANCM status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

FGFR1 is altered in 2.11% of pancreatic carcinoma patients [2].

FGFR1 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR1 status and pancreatic carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

FGFR2 is altered in 0.88% of pancreatic carcinoma patients [2].

FGFR2 is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FGFR2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

FGFR3 is altered in 1.2% of pancreatic carcinoma patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 is altered in 1.09% of pancreatic carcinoma patients [2].

FLT1 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FLT1 status and pancreatic carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

FLT3 is altered in 0.96% of pancreatic carcinoma patients [2].

FLT3 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

FLT4 is altered in 1.62% of pancreatic carcinoma patients [2].

FLT4 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FLT4 status and pancreatic carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

FRK is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FRK status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FZD1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD10 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD3 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD4 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD4 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD5 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD5 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD6 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD6 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD7 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD7 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD8 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD8 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD9 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD9 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

GATA3 is altered in 0.33% of pancreatic carcinoma patients [2].

GATA3 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

HDAC1 is altered in 0.67% of pancreatic carcinoma patients [2].

HDAC1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

HDAC2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

HGF is altered in 0.78% of pancreatic carcinoma patients [2].

HGF is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

HRAS is altered in 0.2% of pancreatic carcinoma patients [2].

HRAS is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HRAS status and pancreatic carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

IDH1 is altered in 0.48% of pancreatic carcinoma patients [2].

IDH1 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain IDH1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

IDH2 is altered in 0.48% of pancreatic carcinoma patients [2].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDM6A is altered in 4.07% of pancreatic carcinoma patients [2].

KDM6A is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KDR is altered in 1.25% of pancreatic carcinoma patients [2].

KDR is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KDR status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

KEAP1 is altered in 1.21% of pancreatic carcinoma patients [2].

KEAP1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KIT is altered in 0.62% of pancreatic carcinoma patients [2].

KIT is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KIT status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

KMT2D is altered in 6.1% of pancreatic carcinoma patients [2].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KRAS is altered in 86.36% of pancreatic carcinoma patients [2].

KRAS is an inclusion eligibility criterion in 12 clinical trials for pancreatic carcinoma, of which 9 are open and 3 are closed. Of the trials that contain KRAS status and pancreatic carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 6 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (1 open) [3].

LRP5 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP5 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

LRP6 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP6 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAGI2 is altered in 0.4% of pancreatic carcinoma patients [2].

MAGI2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MAGI2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MAP2K1 is altered in 0.21% of pancreatic carcinoma patients [2].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K2 is altered in 0.43% of pancreatic carcinoma patients [2].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K4 is altered in 2.36% of pancreatic carcinoma patients [2].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP3K1 is altered in 0.97% of pancreatic carcinoma patients [2].

MAP3K1 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MAP3K1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].

MAPK1 is altered in 0.19% of pancreatic carcinoma patients [2].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAPK11 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK11 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MDM2 is altered in 1.01% of pancreatic carcinoma patients [2].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is altered in 0.33% of pancreatic carcinoma patients [2].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MED12 is altered in 1.67% of pancreatic carcinoma patients [2].

MED12 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MET is altered in 0.89% of pancreatic carcinoma patients [2].

MET is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLH1 is altered in 0.71% of pancreatic carcinoma patients [2].

MLH1 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MLH1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MLH3 is altered in 0.87% of pancreatic carcinoma patients [2].

MLH3 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MLH3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MRE11A is altered in 0.39% of pancreatic carcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 4 clinical trials for pancreatic carcinoma, of which 4 are open and 0 are closed. Of the trials that contain MRE11A status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

MSH2 is altered in 1.18% of pancreatic carcinoma patients [2].

MSH2 is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MSH2 status and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MSH3 is altered in 0.62% of pancreatic carcinoma patients [2].

MSH3 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MSH6 is altered in 1.33% of pancreatic carcinoma patients [2].

MSH6 is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MSH6 status and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MST1R is altered in 0.17% of pancreatic carcinoma patients [2].

MST1R is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MST1R status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MTOR is altered in 1.24% of pancreatic carcinoma patients [2].

MTOR is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MTOR status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MUTYH is altered in 0.55% of pancreatic carcinoma patients [2].

MUTYH is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MUTYH status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC is altered in 3.79% of pancreatic carcinoma patients [2].

MYC is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MYC status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].

NBN is altered in 1.05% of pancreatic carcinoma patients [2].

NBN is an inclusion eligibility criterion in 4 clinical trials for pancreatic carcinoma, of which 4 are open and 0 are closed. Of the trials that contain NBN status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

NF1 is altered in 1.78% of pancreatic carcinoma patients [2].

NF1 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NF1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].

NF2 is altered in 0.93% of pancreatic carcinoma patients [2].

NF2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH1 is altered in 2.03% of pancreatic carcinoma patients [2].

NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH2 is altered in 1.84% of pancreatic carcinoma patients [2].

NOTCH2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NPM1 is altered in 0.31% of pancreatic carcinoma patients [2].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NRAS is altered in 0.74% of pancreatic carcinoma patients [2].

NRAS is an inclusion eligibility criterion in 5 clinical trials for pancreatic carcinoma, of which 4 are open and 1 is closed. Of the trials that contain NRAS status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [3].

NRG1 is altered in 0.47% of pancreatic carcinoma patients [2].

NRG1 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NRG1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

NSD1 is altered in 1.14% of pancreatic carcinoma patients [2].

NSD1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NTRK1 is altered in 1.83% of pancreatic carcinoma patients [2].

NTRK1 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

NTRK2 is altered in 0.4% of pancreatic carcinoma patients [2].

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK3 is altered in 1.08% of pancreatic carcinoma patients [2].

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PALB2 is altered in 1.29% of pancreatic carcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 7 clinical trials for pancreatic carcinoma, of which 7 are open and 0 are closed. Of the trials that contain PALB2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [3].

PARP1 is altered in 0.64% of pancreatic carcinoma patients [2].

PARP1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PARP2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PCNA is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is altered in 0.59% of pancreatic carcinoma patients [2].

PDGFRA is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PDGFRA status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

PDGFRB is altered in 1.05% of pancreatic carcinoma patients [2].

PDGFRB is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRB status and pancreatic carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

PIK3C2B is altered in 1.63% of pancreatic carcinoma patients [2].

PIK3C2B is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PIK3CA is altered in 2.92% of pancreatic carcinoma patients [2].

PIK3CA is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PIK3CA status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

PIK3CB is altered in 0.37% of pancreatic carcinoma patients [2].

PIK3CB is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CB status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PIK3CG is altered in 0.97% of pancreatic carcinoma patients [2].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R1 is altered in 0.96% of pancreatic carcinoma patients [2].

PIK3R1 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PIK3R1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].

PIK3R2 is altered in 0.38% of pancreatic carcinoma patients [2].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PMS1 is altered in 0.4% of pancreatic carcinoma patients [2].

PMS1 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PMS1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

PMS2 is altered in 0.85% of pancreatic carcinoma patients [2].

PMS2 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PMS2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

POLD1 is altered in 1.12% of pancreatic carcinoma patients [2].

POLD1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE is altered in 1.52% of pancreatic carcinoma patients [2].

POLE is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

PPP2R1A is altered in 0.5% of pancreatic carcinoma patients [2].

PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R1A status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R2A status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTCH1 is altered in 1.59% of pancreatic carcinoma patients [2].

PTCH1 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PTCH1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

PTEN is altered in 1.11% of pancreatic carcinoma patients [2].

PTEN is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PTPN11 is altered in 0.33% of pancreatic carcinoma patients [2].

PTPN11 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTPN11 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RAD50 is altered in 1.03% of pancreatic carcinoma patients [2].

RAD50 is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAD50 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

RAD51 is altered in 0.15% of pancreatic carcinoma patients [2].

RAD51 is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAD51 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

RAD51B is altered in 0.13% of pancreatic carcinoma patients [2].

RAD51B is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAD51B status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

RAD51C is altered in 0.43% of pancreatic carcinoma patients [2].

RAD51C is an inclusion eligibility criterion in 4 clinical trials for pancreatic carcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD51C status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

RAD51D is altered in 0.17% of pancreatic carcinoma patients [2].

RAD51D is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAD51D status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

RAD54L is altered in 0.42% of pancreatic carcinoma patients [2].

RAD54L is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAD54L status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

RAF1 is altered in 0.54% of pancreatic carcinoma patients [2].

RAF1 is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAF1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

RB1 is altered in 2.62% of pancreatic carcinoma patients [2].

RB1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RET is altered in 1.3% of pancreatic carcinoma patients [2].

RET is an inclusion eligibility criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RET status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

RFC1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC3 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC4 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC5 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RICTOR is altered in 1.33% of pancreatic carcinoma patients [2].

RICTOR is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RICTOR status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

RNF43 is altered in 6.04% of pancreatic carcinoma patients [2].

RNF43 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ROS1 is altered in 2.02% of pancreatic carcinoma patients [2].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA1 is altered in 0.53% of pancreatic carcinoma patients [2].

RPA1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA3 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA4 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPTOR is altered in 0.75% of pancreatic carcinoma patients [2].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RSPO1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RSPO1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RUNX1 is altered in 0.8% of pancreatic carcinoma patients [2].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SETD2 is altered in 2.02% of pancreatic carcinoma patients [2].

SETD2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SETD2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SLX4 is altered in 1.39% of pancreatic carcinoma patients [2].

SLX4 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SLX4 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

SMARCA4 is altered in 2.93% of pancreatic carcinoma patients [2].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SMARCB1 is altered in 0.27% of pancreatic carcinoma patients [2].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMO is altered in 0.91% of pancreatic carcinoma patients [2].

SMO is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SOX9 is altered in 1.1% of pancreatic carcinoma patients [2].

SOX9 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SOX9 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SRC is altered in 0.97% of pancreatic carcinoma patients [2].

SRC is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SSBP1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

STAG2 is altered in 0.87% of pancreatic carcinoma patients [2].

STAG2 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain STAG2 status and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (1 open) [3].

STK11 is altered in 2.09% of pancreatic carcinoma patients [2].

STK11 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain STK11 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

TAF1 is altered in 2.59% of pancreatic carcinoma patients [2].

TAF1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TBX3 is altered in 0.88% of pancreatic carcinoma patients [2].

TBX3 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TBX3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TEK is altered in 1.39% of pancreatic carcinoma patients [2].

TEK is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TET2 is altered in 1.97% of pancreatic carcinoma patients [2].

TET2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TP53 is altered in 68.91% of pancreatic carcinoma patients [2].

TP53 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain TP53 status and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (1 open) [3].

TRNAK2 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TRNAK2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC1 is altered in 0.64% of pancreatic carcinoma patients [2].

TSC1 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TSC1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

TSC2 is altered in 1.89% of pancreatic carcinoma patients [2].

TSC2 is an inclusion eligibility criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TSC2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

VEGFA is altered in 0.62% of pancreatic carcinoma patients [2].

VEGFA is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFB is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFC is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VHL is altered in 0.33% of pancreatic carcinoma patients [2].

VHL is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

WNT1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains WNT1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

XPO1 is altered in 0.47% of pancreatic carcinoma patients [2].

XPO1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains XPO1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

XRCC1 is altered in 0.85% of pancreatic carcinoma patients [2].

XRCC1 is an inclusion eligibility criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].